The studies described here were undertaken to evaluate the activity of MEDI3622 in a heterogeneous panel of CRC patient-derived xenograft (PDX) models, comprised of both KRAS-mutant (KRASMT) and KRAS-wild type (KRASWT) models. Here, KRAS is linked to colorectal carcinoma.